Stem cell heart muscle therapy for weak heart after prior heart attack
Part of Heart & circulation clinical trials.
This Phase 1 study tests a treatment made from stem cells to grow heart muscle cells (“cardiomyocytes”) for people with long-lasting (chronic) heart weakness after a prior heart attack. It aims to see if the therapy can improve heart function and is safe in carefully selected patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 21 to under 80 years old
- You have had a prior heart attack and have evidence of lasting heart muscle damage (shown on imaging) from blocked heart arteries
- Your heart pumping strength (ejection fraction) is below 40% and you have heart failure symptoms in the last 6 months
- You are already on the usual “maximum” heart failure medicines at stable doses (or you have a reason you can’t take some)
- You need a cardiac catheterization (a heart procedure done through blood vessels) within about 5–10 weeks of screening
- You have an implanted defibrillator (AICD) in place, and it has not fired in the last 60 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
This trial tests whether heart muscle cells made from stem cells, injected into the heart, can improve heart function in people with heart failure and a weak heart pump. It may be an option for those who are not getting enough help from other treatments.
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
This trial tests if umbilical cord stem cells, given alongside standard care, can help people who have had a major heart attack (STEMI). The cells are infused into the heart artery to possibly improve heart function. You may qualify if you are between 20 and 76, had a heart attack within the last 12 hours, and received a stent, and your heart's pumping ability is moderately reduced.
This early-phase study tests a lab-made heart tissue (“engineered myocardium”) placed surgically to help the heart work better in people with advanced heart failure. It mainly checks safety first, and also looks for signs the patch can improve heart function in selected patients.
This study tests a new cell therapy (MiSaver) for people who have had a heart attack and whose heart is not pumping as strongly as it should. It aims to see if these cells can help the heart recover when stents or bypass surgery aren't an option.
Hear when a new Chronic Ischemic Left Ventricular Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.